Hsiao Dee Lieu, M.D., F.A.C.C.
Vice President of Clinical Research
Dr. Lieu has over 13 years of experience in the biopharmaceutical/biotech industry including academic medicine (cardiology), molecular cardiology research, translational and clinical drug development including execution of large multinational Phase III clinical trials and responsibility for interactions with regulatory authorities and key opinion leaders in the U.S., Canada, and Europe.
Prior to joining Nile, Dr. Lieu served as the Director of Clinical Development for Portola Pharmaceuticals, Inc.
In this role, Dr. Lieu
was responsible for the overall clinical development plan and execution for early- to late-stage intravenous and oral molecules including a large ADP
antagonist program in acute coronary syndrome.
Before joining Portola, Dr. Lieu served as the Director of Clinical Research and Development at CV Therapeutics, Inc.
In this role, Dr. Lieu led the clinical development program for regadenoson, which included two successful large multinational Phase III trials.
Dr. Lieu also worked as a researcher at the J. David Gladstone Institute of Cardiovascular Disease at the University of California at San Francisco (UCSF) conducting molecular cardiology research in gene manipulation and induction of cardiomyopathy and atherosclerosis regression.
Dr. Lieu currently serves as Assistant Clinical Professor of Medicine, Cardiology Division at UCSF.
clinical cardiology fellowship at UCSF
residency in internal medicine at Columbia University
He received his M.D. from the Albert Einstein College of Medicine with distinction in molecular biology research, and his B.A. from New York University.